We’ve all had a moment where we arrived at the grocery store and can’t remember passing any of the stoplights along the way. We’re halfway down an aisle and scrambling to remember what we even needed. Our mind is in overdrive trying to sort through our ever-growing to-do list. We’ve been there when just making it through the next task is hard. But the normal stresses of life aren’t the only thing YOU have to deal with. Nora McInerny hosts The Head Start: Embracing the Journey, a new podcast ...
…
continue reading
Content provided by HCPLive Podcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HCPLive Podcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
HCPLive Under 5 Audio Recap: Week of 04/27
MP3•Episode home
Manage episode 480601917 series 3310601
Content provided by HCPLive Podcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HCPLive Podcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for April 21-April 27, 2025:
FDA Approves Pz-cel (Zevaskyn) Gene Therapy for RDEB
The FDA has approved pz-cel, the first autologous gene therapy for RDEB, following pivotal Phase 3 data demonstrating efficacy and safety in wound healing.
FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis
Upadacitinib has been approved for giant cell arteritis, supported by Phase 3 data showing its potential to induce sustained remission and reduce corticosteroid reliance.
FDA Approves Nipocalimab Generalized Myasthenia Gravis for Adults, Children
Nipocalimab received FDA approval for gMG in antibody-positive patients aged ≥12, expanding therapeutic options across major serotypes.
Semaglutide Improves Steatohepatitis, Fibrosis in Phase 3 MASH Trial
Phase 3 trial results show semaglutide significantly improves steatohepatitis and fibrosis markers in patients with MASH, without worsening liver histology.
Increased Fasting Blood Glucose Triples Risk of Heart Damage in Adolescents
International data links elevated fasting glucose and insulin resistance in adolescence to markedly increased future risk of heart damage, especially among females.
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for April 21-April 27, 2025:
FDA Approves Pz-cel (Zevaskyn) Gene Therapy for RDEB
The FDA has approved pz-cel, the first autologous gene therapy for RDEB, following pivotal Phase 3 data demonstrating efficacy and safety in wound healing.
FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis
Upadacitinib has been approved for giant cell arteritis, supported by Phase 3 data showing its potential to induce sustained remission and reduce corticosteroid reliance.
FDA Approves Nipocalimab Generalized Myasthenia Gravis for Adults, Children
Nipocalimab received FDA approval for gMG in antibody-positive patients aged ≥12, expanding therapeutic options across major serotypes.
Semaglutide Improves Steatohepatitis, Fibrosis in Phase 3 MASH Trial
Phase 3 trial results show semaglutide significantly improves steatohepatitis and fibrosis markers in patients with MASH, without worsening liver histology.
Increased Fasting Blood Glucose Triples Risk of Heart Damage in Adolescents
International data links elevated fasting glucose and insulin resistance in adolescence to markedly increased future risk of heart damage, especially among females.
190 episodes
MP3•Episode home
Manage episode 480601917 series 3310601
Content provided by HCPLive Podcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HCPLive Podcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for April 21-April 27, 2025:
FDA Approves Pz-cel (Zevaskyn) Gene Therapy for RDEB
The FDA has approved pz-cel, the first autologous gene therapy for RDEB, following pivotal Phase 3 data demonstrating efficacy and safety in wound healing.
FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis
Upadacitinib has been approved for giant cell arteritis, supported by Phase 3 data showing its potential to induce sustained remission and reduce corticosteroid reliance.
FDA Approves Nipocalimab Generalized Myasthenia Gravis for Adults, Children
Nipocalimab received FDA approval for gMG in antibody-positive patients aged ≥12, expanding therapeutic options across major serotypes.
Semaglutide Improves Steatohepatitis, Fibrosis in Phase 3 MASH Trial
Phase 3 trial results show semaglutide significantly improves steatohepatitis and fibrosis markers in patients with MASH, without worsening liver histology.
Increased Fasting Blood Glucose Triples Risk of Heart Damage in Adolescents
International data links elevated fasting glucose and insulin resistance in adolescence to markedly increased future risk of heart damage, especially among females.
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for April 21-April 27, 2025:
FDA Approves Pz-cel (Zevaskyn) Gene Therapy for RDEB
The FDA has approved pz-cel, the first autologous gene therapy for RDEB, following pivotal Phase 3 data demonstrating efficacy and safety in wound healing.
FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis
Upadacitinib has been approved for giant cell arteritis, supported by Phase 3 data showing its potential to induce sustained remission and reduce corticosteroid reliance.
FDA Approves Nipocalimab Generalized Myasthenia Gravis for Adults, Children
Nipocalimab received FDA approval for gMG in antibody-positive patients aged ≥12, expanding therapeutic options across major serotypes.
Semaglutide Improves Steatohepatitis, Fibrosis in Phase 3 MASH Trial
Phase 3 trial results show semaglutide significantly improves steatohepatitis and fibrosis markers in patients with MASH, without worsening liver histology.
Increased Fasting Blood Glucose Triples Risk of Heart Damage in Adolescents
International data links elevated fasting glucose and insulin resistance in adolescence to markedly increased future risk of heart damage, especially among females.
190 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.